Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...
Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.
(MENAFN- GlobeNewsWire - Nasdaq) MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces ...
Group CEO, Dr. Christian Behrenbruch, commented on the result: “2024 has been an extraordinary year for Telix. We generated strong financial growth while investing for the future. The Precision ...
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, ...